A protein associated with leukaemia has been linked to the brain injury seen in Alzheimer's disease in a new study.
Research published in the Journal of Alzheimer's Disease found that a molecule, known as c-Abl was part of the plaques and tangles in the brain which are characteristic of the condition.
Scientists could now use animal models to test the benefit of drugs that turn off the c-Abl protein.
"We have a great model to test compounds for Alzheimer's disease. Will regulating c-Abl make a difference for patients? We won't know unless we try it in double blind clinical trials," said Dr Peter Davis, head of the Feinstein Institute's Litwin-Zucker Center for Research in Alzheimer's Disease.
Meanwhile, two proteins involved in Alzheimer's disease may combine to damage the energy centres of brain cells, causing cell death, according to a study published online in journal Neurobiology of Aging.
Serious Law, award winning brain injury law firm
Posted by Matthew Heap
